For two decades, metabolic research was dominated by GLP-1. The incretin that scientists almost forgot was amylin — a peptide co-secreted with insulin from pancreatic beta cells that regulates appetite through entirely different brain circuits than GLP-1.

Amylin acts primarily through the area postrema and nucleus of the solitary tract in the brainstem — regions distinct from the hypothalamic circuits targeted by GLP-1. This anatomical separation means amylin and GLP-1 regulate appetite through parallel, non-redundant pathways.¹

Cagrilinitide is a long-acting amylin receptor agonist designed to exploit this parallelism. Its development was driven by a simple hypothesis: if two independent pathways both suppress appetite, targeting both simultaneously should produce greater appetite reduction than targeting either alone.

The key insight: amylin primarily controls how much you eat per meal (meal size), while GLP-1 primarily controls how often you want to eat (appetite/satiety). Together, they address both dimensions of food intake.²

The most significant cagrilinitide research involves its combination with semaglutide — the program known as CagriSema. Early clinical data showed that co-administration of cagrilinitide and semaglutide produced greater weight reduction than semaglutide alone, consistent with the dual-pathway hypothesis.³

This combination approach is conceptually different from dual incretin agonism (tirzepatide targeting GIP + GLP-1 through one molecule). CagriSema uses two separate molecules targeting two separate receptor systems. The pharmacological question is whether this "two-drug" approach achieves similar or superior results to the "one-drug, two-receptor" approach of tirzepatide.

Amylin receptors are unusual in receptor pharmacology. They aren't standalone proteins — they're heterodimers formed by the calcitonin receptor (CTR) combined with receptor activity-modifying proteins (RAMPs). Different CTR/RAMP combinations create different amylin receptor subtypes (AMY1, AMY2, AMY3) with different tissue distributions and pharmacological properties.⁴

This receptor complexity creates a research challenge: amylin agonists may have different effects depending on which AMY subtype predominates in a given tissue. Cagrilinitide's subtype selectivity profile and how it varies across tissues is an active area of investigation.

Cagrilinitide is in active clinical development — Phase 3 trials are ongoing. Published efficacy data comes primarily from Phase 2 studies with relatively small sample sizes. Long-term outcomes are not yet available. The CagriSema combination has not yet been approved by any regulatory agency.